Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

October 31, 2017

Conditions
SchizophreniaCognitionPsychosis
Interventions
DRUG

Curcumin

360 mg/day (divided into twice daily oral doses)

DRUG

Placebo

"Inactive, matched placebo (Sugar Pill)"

Trial Locations (1)

90073

VA Greater Los Angeles, Los Angeles

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

collaborator

Theravalues, Inc.

INDUSTRY

collaborator

University of California, Los Angeles

OTHER

lead

VA Greater Los Angeles Healthcare System

FED

NCT02104752 - Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia | Biotech Hunter | Biotech Hunter